4th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference UK/EU

150+

Attendees

20+

Speakers

10+

Networking Hours

5+

Sessions

Leveraging next gen technologies beyond conventional biomarker drug discovery

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

20+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Challenges in NGS based CDx and the Importance of imaging biomarkers for precision medicine.

Opportunity to develop long-lasting business relationships and networking opportunities with senior peers. Get the Opportunity to get your queries handled by Biomarker experts in one on one session.

Facilitated networking sessions to ensure quality interactions along with Case studies from experts who have successfully created and developed a biomarker

Clinical biomarker identification and qualification
Biomarkers and personalized medicine
Assay development and validation
NGS and novel technologies in biomarker discovery
Commercialization of biomarkers in therapeutic and CDx applications

Researchers, scientists, clinicians, academicians and professionals From Pharmaceutical companies, Bio-pharma companies, Universities and Research Institutes.

Departments:

Biomarker discovery/development | Translational research | Clinical Biomarker | Biomarkers in IO and Neurological disorders

CONFERENCE AGENDA

Registration	08:15 - 08:55
Welcome note from MarketsandMarkets	08:55 - 09:00
Opening Remarks from the Chairman Patrick Brossard, Principal Clinical Pharmacologist, SOBI	09:00 - 09:10
The use of biomarkers and population PK/PD modeling to define dosing regimen for phase II and III clinical trials and their potential use to guide dosing adaptation Patrick Brossard, Principal Clinical Pharmacologist, SOBI	09:10 - 09:45
Biomarker Discovery and Translational Drug Development
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	09:45 - 10:15
Metabolomic applications in oncology Heino Heyman, Metabolomics Application Specialist, Metabolon	10:15 - 10:50
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:50 - 11:30
New biomarkers predicting therapy with RNA activation Nagy Habib, Founder and Head of R&D, MiNA Therapeutics	11:30 - 12:05
PD-1/PD-L1: A New Biomarker to Stratify Patients to Immunotherapy in NSCLC James Miles, Product Manager, HAWK Biosystems	12:05 - 12:40
Biomarker support for tumour-associated antigen targeting Humabodies delivering CD137 agonism to the tumour microenvironment Andrew Pierce, Vice President, Translational Biology, Crescendo Biologics	12:40 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Biomarkers in Personalized Medicine
Challenges Facing Analytical Development for ATMPs Batika Rana, Senior Scientist, Orchard Therapeutics	14:15 - 14:50
3D mechanistic visualisation of subcellular cancer dynamics after nanodrug targeting Sreejith Raveendran, Assistant Professor, Teesside University	14:50 - 15:25
Single cell analysis approaches to uncover mechanisms that allow bladder cancer cells to tolerate drug-induced replication stress. Bart Westendorp, Assistant Professor, Department of Biomolecular Health Sciences, Utrecht University, The Netherlands	15:25 - 16:00
Biomarker Toolkit: a tool aiming to quantifiably assess biomarker impact and guide development Katerina-Vanessa Savva, Researcher, Imperial College London	16:00 - 16:35
Closing Remarks from the Chairman Patrick Brossard, Principal Clinical Pharmacologist, SOBI	16:30 - 16:40
Drinks Reception \| Evening Refreshments \| One-to-One Networking Meetings	16:40 - 17:40
End of Day 1	17:40 - 17:40

Registration	08:15 - 08:55
Welcome note from MarketsandMarkets	08:55 - 09:00
Opening Remarks from the Chairman Patrick Brossard, Principal Clinical Pharmacologist, SOBI	09:00 - 09:10
Keynote Presentation- Digital biomarkers for stratified neuroscience drug development Jennifer Barnett , CEO, Monument Therapeutics	09:10 - 09:45
Biomarkers and their Applications
RNAa in chronic disease, oncology, and genetic medicine Brid Ryan, Vice President, MiNA Therapeutics	09:45 - 10:15
Secretion based Single Cell Analysis and Sorting Alain Wagner, Co-founder, MicroOmiX Tech	10:15 - 10:50
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:50 - 11:30
Circulating biomarkers for cancer diagnosis and precision medicine - examples in prostate cancer Yong-Jie Lu , Professor of Molecular Oncology (Barts Cancer Institute), Queen Mary University of London (QMUL)	11:30 - 12:05
Eliminating Care Inequality with a Radically Cost-Effective Test for Evaluating Patient Risk in Early-Stage HR+ Breast Cancer Hemmel Amrania, Research Scientist, Imperial College London	12:05 - 12:40
An Unsupervised Data-driven Anomaly Detection and biomarker discovery Approach for Detection of Adverse Health Conditions in People Living with Dementia Samaneh Kouchaki, Lecturer, Machine Learning, University of Surrey	12:40 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Bioinformatics approaches for classification of breast cancers Jelmar Quist, Cancer Bioinformatician, King’s College London	14:15 - 14:50
Closing Remarks from the Chairperson Patrick Brossard, Principal Clinical Pharmacologist, SOBI	14:50 - 15:00
End of Conference	15:00 - 15:00